Status: Not yet recruiting
Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer
This study aim to evaluate the efficacy and safety of Bozitinib combined with chemotherapy as radical treatment for stage IIA-IIIC MET-altered non-small cell lung cancer
Participants needed: 34
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Pulmonary Hospital, Shanghai, ChinaUpdated: Sep 4, 2025
Eligibility criteria
Signed informed consent. [+16]
All participants must undergo brain imaging (MRI or contrast-enhanced CT) prior... [+9]